PAINREFORM LTD. IS-,01 Aktie

PainReform announces that the annual general meeting will take place on December 30, 2025 at 3:00 p.m. Israel time in the offices of Amit, Pollak, Matalon & Co. in Tel Aviv. The company has distributed a notice of meeting and a proxy statement that describe the agenda items to be voted on and the voting procedures. Shareholders may attend in person or by proxy; a proxy form for written votes has been provided. Details on the agenda and voting procedures are included in the SEC filing. » More on de.investing.com

PainReform reports a net loss of $2.3m for H1 2025 versus $12.8m a year earlier, and shows $3.5m in cash and positive working capital. The company continues its dual strategy: acquisition of a majority stake in LayerBio including OcuRing-K and continuation of PRF-110 development, as well as completion of the MyDeepSolar app, entry into the NVIDIA Connect Program and a commercial agreement for a 92 MW pilot project in Romania. Despite operational progress, InvestingPro rates the financial situation 1.45/5 and flags high cash burn with negative EBITDA over the last twelve months. » More on de.investing.com

Painreform's stock dropped by 11% after the company announced a strategic investment in LayerBio. Painreform will acquire a majority stake in LayerBio and invest up to $3 million to expand its pipeline in non-opioid pain therapies. The investment aims to advance the development of the ophthalmic product OcuRing-K, while LayerBio will continue to operate independently. » More on de.investing.com